Transmural remission improves clinical outcomes up to 5 years in Crohn's disease.
Fernandes SR, Serrazina J, Botto IA, Leal T, Guimarães A, Garcia JL, Rosa I, Prata R, Carvalho D, Neves J, Campelo P, Ventura S, Silva A, Coelho M, Sequeira C, Oliveira AP, Portela F, Ministro P, Tavares de Sousa H, Ramos J, Claro I, Gonçalves R, Correia LA, Marinho RT, Cortez-Pinto H, Magro F.
Fernandes SR, et al. Among authors: leal t.
United European Gastroenterol J. 2023 Feb;11(1):51-59. doi: 10.1002/ueg2.12356. Epub 2022 Dec 27.
United European Gastroenterol J. 2023.
PMID: 36575615
Free PMC article.
INTRODUCTION: Evidence supporting transmural remission (TR) as a long-term treatment target in Crohn's disease (CD) is still unavailable. Less stringent but more reachable targets such as isolated endoscopic (IER) or radiologic remission (IRR) may also be acceptable option …
INTRODUCTION: Evidence supporting transmural remission (TR) as a long-term treatment target in Crohn's disease (CD) is still unavaila …